Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Amplia Therapeutics Ltd. ( (AU:ATX) ) has issued an announcement.
Amplia Therapeutics Limited has announced a change in the exercise prices of its unlisted options following a successful A$13 million capital raising completed in December 2024. The adjustments, set to take effect on February 20, 2025, are in line with ASX Listing Rule 6.22.2 and will involve distributing replacement holding statements and application forms to all option holders, potentially impacting stakeholder engagement and financial strategies.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company focusing on the development of Focal Adhesion Kinase (FAK) inhibitors aimed at treating cancer and fibrosis. The company has a particular emphasis on fibrotic cancers, such as pancreatic cancer, and is also exploring the role of FAK in chronic diseases like idiopathic pulmonary fibrosis.
YTD Price Performance: 47.50%
Average Trading Volume: 24,128
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $20.29M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.
